ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic agents"

  • Abstract Number: 1444 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions

    Jose Inciarte-Mundo1, Maria Victoria Hernández2, Sonia Cabrera1, Virginia Ruiz-Esquide3, Julio Ramirez1, Juan D. Cañete2, Jordi Yague4 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Clinic, Barcelona, Spain, 4Hospital Clínic / IDIBAPS, Barcelona, Spain

    Background/Purpose: Biological therapy has proved efficacious in various chronic inflammatory arthropathies but, in practice, clinical efficacy is reduced in some patients, suggesting drug-induced immunogenicity as…
  • Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting

    Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry

    Vance J. Bray1, Adam W. Bagley2, Sterling G. West3, Carol J. Etzel4, Joel M. Kremer5 and Jason R. Kolfenbach6, 1Denver Arthritis Clinic, Denver, CO, 2Internal Medicine, University of Colorado School of Medicine, Aurora, CO, 3Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Department of Epidemiology, UT MD Anderson, Houston, TX, 5Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption.  Denosumab prevents RANKL from activating RANK on the cell…
  • Abstract Number: 2169 • 2013 ACR/ARHP Annual Meeting

    Short Term Efficacy Of Biologic Agents In Patients With Systemic Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Trials

    Simon Tarp1, Gil Amarilyo2, Ivan Foeldvari3, Neta Cohen4, Tracy D. Pope5, Jennifer M.P. Woo6, Robin Christensen1 and Daniel Furst5, 1Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 2Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 4Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 5David Geffen School of Medicine, University of California, Los Angeles, CA, 6Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe subtype of JIA, which includes systemic features such as fever, rash, elevated inflammatory markers along with…
  • Abstract Number: 1451 • 2013 ACR/ARHP Annual Meeting

    Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States

    Siva Narayanan1, Yao Lu2, Richard Hutchings2 and Amanda Baskett2, 1Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, 2Ipsos Healthcare, London, United Kingdom

    Background/Purpose: Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed…
  • Abstract Number: 462 • 2013 ACR/ARHP Annual Meeting

    Reduced Response To Biologic Treatments in  Rheumatoid Arthritis Patients Affected By Arterial Hypertension

    Marco Antivalle1, Michel Chevallard2, Michele Battellino2, Alberto Batticciotto3, Maria Chiara Ditto2, Alessandra Mutti1, Federica Rigamonti4, Valentina Varisco2, Sara Bongiovanni2, Fabiola Atzeni5 and Piercarlo Sarzi-Puttini6, 1Rheumatology, L. Sacco University Hospital, Milano, Italy, 2Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, 3Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 4Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, 5Rheumatology, Rheumatology Unit, L. Sacco University Hospital, MiIano, Italy, 6Rheumatology Unit, L. Sacco University Hospital, Milan, Italy

    Background/Purpose: Several reports show that the presence of comorbidities negatively influences both functional status (1) and quality of life (2) in rheumatoid arthritis (RA).  No…
  • Abstract Number: 2056 • 2013 ACR/ARHP Annual Meeting

    Use Of Biologics In Polymyositis and Dermatomyositis – A National Register Study

    John Svensson1, Anna Tjärnlund2, Balsam Hanna3, Sara Magnusson Bucher4, Johan Askling5, Ingrid E. Lundberg6 and Maryam Dastmalchi7, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Stockholm, Sweden, 3Rheumatology Unit, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Rheumatology unit, Örebro University Hospital, Örebro, Sweden, 5Karolinska Institutet, Stockholm, Sweden, 6Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 7Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Biologics have been used off-label in treatment of refractory polymyositis (PM) and dermatomyositis (DM). In this study we aimed to describe the use of…
  • Abstract Number: 1419 • 2013 ACR/ARHP Annual Meeting

    Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial

    Sofie H.M. Manders1, Wietske Kievit2, Herman L.M. Brus3, Hein J. Bernelot Moens4, Andre Hartkamp5, Reinhard Bos6, Elisabeth Brouwer7, Henk Visser8, Harald E. Vonkeman9, Rene Westhovens10, Mart A.F.J. van de Laar11 and Piet LCM Van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3TweeSteden Ziekenhuis, Tilburg, Netherlands, 4Ziekenhuisgroep Twente, Almelo, Netherlands, 5Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, 6Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, 7Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 8Rheumatology, Rijnstate, Arnhem, Netherlands, 9Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, 10Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 11Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands

    Background/Purpose: The best treatment option after a patient has failed a first TNFi is still unknown. Therefore the objective of this randomized open label study…
  • Abstract Number: 448 • 2013 ACR/ARHP Annual Meeting

    Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards:  A Registry-Based Comparison Study

    Cem Gabay1, Myriam Riek2, Merete Lund Hetland3, Ulrik Tarp4, K. Pavelka5, Matija Tomsic6, Helena Canhao7, Katerina Chatzidionysiou8, R.F. van Vollenhoven9, Galina Lukina10, E. Nasonov11, Dan C. Nordström12, Elisabeth Lie13, Ioan Ancuta14, Estibaliz Loza Santamaria15, Piet Van Riel16 and Tore K. Kvien13, 1Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2SCQM Registry, Zurich, Switzerland, 3DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 5Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 6Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, 7Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 8Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, 9Karolinska Institute, Stockholm, Sweden, 10ARBITER, Institute of Rheumatology, Moscow, Russia, 11Institute of Rheumatology, Moscow, Russia, 12ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 13Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 14“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 15Instituto de salud Musculoesqueletica, Madrid, Spain, 16Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Tocilizumab (TCZ) is efficacious in monotherapy and in combination with methotrexate (MTX) or other DMARDs. However, longitudinal data from large registry populations are missing.…
  • Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting

    Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices

    Mattia Baldini1, Patrizia Aiello1, Mirta Tiraboschi1, Maria Grazia Sabbadini2 and Elena Baldissera1, 1Internal Medicine and Clinical Immunology, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy, 2Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy

    Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…
  • Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting

    Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)

    Kim Hørslev-Petersen1, Lykke Midtbøll Ørnbjerg2, Merete Lund Hetland3, Peter Junker4, Jan Pødenphant5, Torkell Ellingsen6, Palle Ahlqvist7, Hanne M. Lindegaard8, Asta Linauskas9, Annette Schlemmer10, Mette Y. Dam11, Ib Hansen12, Tine Lottenburger7, Anette Jørgensen13, Sophine B. Krintel14, Johnny Raun15, Christian G. Ammitzbøll11, Julia Johansen14, Mikkel Østergaard16 and Kristian Stengaard-Pedersen11, 1Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, 2Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, 3DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4University of Southern Denmark, Odense, Denmark, 5Copenhagen University at Gentofte, Hellerup, Denmark, 6Silkeborg Regional Hospital, Silkeborg, Denmark, 7University of Southern Denmark, Vejle, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, 9Vendsyssel Hospital, Hjørring, Denmark, 10Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 11Arhus University Hospital, Aarhus, Denmark, 12Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 13Rheumatology, Arhus University Hospital, Aarhus, Denmark, 14Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, 15University of Southern Denmark, Graasten, Denmark, 16Copenhagen University Hospital Glostrup, Copenhagen, Denmark

    Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…
  • Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting

    Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort

    James Bluett1, Catharine Morgan1, Layla Thurston2, Darren Plant1, Ann W. Morgan3, Anthony G. Wilson4, John Isaacs5, Kimme L. Hyrich1, Lis Cordingley1 and Anne Barton1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2Manchester Medical School, The University of Manchester, Manchester, United Kingdom, 3NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 5National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom

    Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
  • Abstract Number: 2841 • 2013 ACR/ARHP Annual Meeting

    Inflammation and Structural Progression In The Sacroiliac Joints Of Patients With Axial Spa Treated With Adalimumab Or Placebo As Assessed By The Berlin and The Spondyloarthritis Research Consortium Of Canada MRI Methods

    Susanne Juhl Pedersen1, Denis Poddubnyy2, Inge Juul Sørensen3, Anne Gitte Loft4, Jens Skjødt Hindrup5, Gorm Thamsborg6, Karsten Asmussen7, Elka Kluger8, Jesper Nørregaard9, Torben Grube Christensen10, Anne G. Jurik11, J.M. Møller12, Thomas Skjødt13, Dorrit Mikkelsen14 and Mikkel Østergaard15, 1Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Department of Rheumatology, Hvidovre Hospital, Copenhagen, Denmark, 4Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, 5Dep. of Rheumatology, Gentofte Hospital, Copenhagen, Denmark, 6Dep. of Rheumatology, Glostrup Hospital, Copenhagen, Denmark, 7Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 8King Christian 10th Rheumatism Hospital at Gråsten, Graasten, Denmark, 9Dep of Rheumatology, Hørsholm Hospital, Hørsholm, Denmark, 10MD, Slagelse, Denmark, 11Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, 12Department of Radiology, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 13Dep. of Radiology, Vejle Hospital, Vejle, Denmark, 14Dep. of Radiology, Aabenraa Hospital, Aabenraa, Denmark, 15Copenhagen University Hospital Glostrup, Copenhagen, Denmark

    Background/Purpose: To investigate changes in inflammation and structural progression in the sacroiliac joints (SIJs) in patients with axial spondyloarthritis (SpA) during treatment with adalimumab and…
  • Abstract Number: 2013 • 2013 ACR/ARHP Annual Meeting

    Biologic Therapy In Refractory Uveitis Of Sarcoidosis. Multicenter Study Of 16 Patients

    Javier Loricera1, Vanesa Calvo-Río2, Ricardo Blanco3, Marina Mesquida4, Alfredo M. Adan4, JM Herreras5, A Aparicio6, MJ Moreno Ramos7, MJ Moreno Martínez7, LF Linares Ferrando7, M Hernández Martínez8, D Peitado-Lopez9, Miguel Cordero-Coma10, Jl García Serrano11, Norberto Ortego11, O Maíz12, A Blanco13, Juan Sánchez-Bursón14, S González-Suárez15, Alejandro Fonollosa16, Montserrat Santos-Gómez2, F. Ortiz-Sanjuán1 and Miguel Angel González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Hospital Marques de Valdecilla, Santander, Spain, 4Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, 5Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, 6Rheumatology., Hospital de Toledo., Toledo, Spain, 7Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, 8Ophthalmology, Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, 9Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, 10Ophthalmology, Hospital de León. Spain, León, Spain, 11Hospital San Cecilio. Granada, Granada, Spain, 12Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, 13Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, 14Hospital de Valme. Sevilla, Sevilla, Spain, 15Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, 16Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain

    Background/Purpose: Uveitis related to sarcoidosis is a potentially severe complication. Corticosteroids are the first line of treatment. In refractory cases or in those with unacceptable…
  • Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting

    Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits

    Arthur Kavanaugh1, Susan J. Lee2,3, Daniel H. Solomon4, Jeffrey D. Greenberg5, Joel M. Kremer6, Lilian Soto7, Carol J. Etzel8,9 and George W. Reed10, 1University of California, San Diego, La Jolla, CA, 2University of California San Diego, La Jolla, CA, 3San Diego Veterans Affairs Medical Center, San Diego, CA, 4Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 5NYU Hospital for Joint Diseases, New York, NY, 6Center for Rheumatology, Albany Medical College, Albany, NY, 7University of California San Diego, San Diego, CA, 8Department of Epidemiology, UT MD Anderson, Houston, TX, 9PO Box 786, Corrona, LLC., Southborough, MA, 10Corrona, LLC., Southborough, MA

    Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…
  • Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting

    Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry

    Louis Bessette1, Denis Choquette2, Diane Sauvageau3, Boulos Haraoui4, Jean Pierre Pelletier2, Jean-Pierre Raynauld3, Edith Villeneuve3 and Louis Coupal2, 1Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 4Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada

    Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology